The KRAS mutational spectrum and its clinical implications in pancreatic cancer

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2024-08-29 DOI:10.1016/j.ccell.2024.08.001

Luigi Perelli, Giannicola Genovese, Giulio F. Draetta

引用次数: 0

Abstract

In this issue of Cancer Cell, McIntyre et al. show that specific mutations in the KRAS proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the KRAS^G12R mutation is enriched in early-stage PDAC, and it is characterized by distinctly activated molecular programs.

查看原文本刊更多论文

胰腺癌 KRAS 基因突变谱及其临床意义

在本期《癌细胞》（Cancer Cell）杂志上，McIntyre 等人发现 KRAS 原癌基因的特定突变会影响胰腺导管腺癌（PDAC）的临床进展。重要的是，他们发现KRASG12R突变在早期PDAC中富集，其特点是分子程序被明显激活。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.